You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
個股熱度排行 | 2月15日港股收盤

根據uSMART輿情監測數據,15日港股交易時段,市場關注指數最高的4只股票是信達生物、藥明生物、藥明康德、四環醫藥。

2月15日—港股關注排行TOP4

輿情變化榜單

信達生物

個股K線圖

關注度第一爲信達生物,該股今日收盤上漲16.75%,報於33.45港元。近5個交易日累計上漲1.52%。在消息面和社交媒體方面,輿情以看多爲主。較被市場關注的消息有:

信達生物與馴鹿醫療共同開發BCMA CAR-T候選產品獲美國FDA孤兒藥資格

招商證券:重申信達生物“買入”評級 目標價110港元

藥明生物

個股K線圖

關注度第二爲藥明生物,該股今日收盤上漲10.09%,報於61.65港元。近5個交易日累計下跌0.96%。在消息面和社交媒體方面,輿情以看多爲主。較被市場關注的消息有:

恆生指數午盤收跌0.7%報24383點 CXO板塊走強 藥明生物漲8.13%

快訊:醫藥外包概念股上漲 藥明康德漲近7%藥明生物漲超6%

藥明康德

個股K線圖

關注度第三爲藥明康德,該股今日收盤上漲12.13%,報於101.70港元。近5個交易日累計上漲0.99%。在消息面和社交媒體方面,輿情以看多爲主。較被市場關注的消息有:

藥明康德反彈8%領跑CXO股 券商看好新冠口服藥下CDMO業務

醫藥外包概念股漲幅擴大 藥明康德漲近11%昭衍新藥漲近10%

四環醫藥

個股K線圖

關注度第四爲四環醫藥,該股今日收盤上漲19.38%,報於1.91港元。近5個交易日累計上漲23.23%。在消息面和社交媒體方面,輿情以看多爲主。較被市場關注的消息有:

醫美概念股走強 四環醫藥漲5.63%

四環醫藥大漲19% CBC集團宣佈已經完成收購Hugel

此外,監測期內有1只股票的輿情出現大扭轉,意味着在消息面上出現了可能影響公司股價趨勢的事件或者轉折。

2月15日—港股輿情轉折預警

輿情變化榜單

信達生物

個股K線圖

信達生物輿情扭轉指數達99,目前輿情方向爲利好,表明公司出現了被投資者視作較大利好的消息。

其中較被市場關注的消息有:

信達生物與馴鹿醫療共同開發BCMA CAR-T候選產品獲美國FDA孤兒藥資格

招商證券:重申信達生物“買入”評級 目標價110港元

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account